AMENDMENTS TO THE CLAIMS

1. - 20. (cancelled)

21. (currently amended) A method for the treatment, curing or prevention of anemia in a patient, which comprises administering to said patient a combination of a Gas6 compound or a DNA sequence encoding a Gas6 compound and erythropoeitin, or an analogue, mutant, variant or derivative of said erythropoeitin, or a physiologically tolerated salt of said EPO derivative, either simultaneously or sequentially, thereby ensuring a synergistic rescue effect on erythropoeisis in said patient.

wherein said erythropoeitin is selected from the group consisting of:

- -a naturally occurring erythropoeitin,
- -a glycosylation variant of erythropoeitin,
- -a point mutant or deletion mutant of erythropoeitin which retains stimulation of the production of red blood cells, and,
- -a physiologically tolerated salt of said naturally occurring erythropotein, glycosylation variant, point mutant or deletion mutant;
- and wherein said Gas6 compound is selected from the group consisting of:
 -wild type Gas6,
- -a fragment of Gas6 lacking the A domain or a fragment of Gas6 consisting essentially of the D domain,
- -a Gas mutant having at least 95 % sequence identity at the amino acid level said Gas6 fragment and retaining the function of activating the Gas6 receptors Axl, Mer and Sky, and,
- -a physiologically tolerated salt of said wild type Gas6, fragment or mutant.
- 22. (cancelled)
- 23. (cancelled)

- 24. (cancelled)
 25. (cancelled)
 26. (cancelled)
 27. (cancelled)
- 28. (withdrawn) The method according to claim 21, wherein said DNA encoding a Gas6 compound is comprised in a vector.
- 29. (withdrawn) The method according to claim 21, wherein said DNA encoding a Gas6 compound is engineered into a cell.
- 30. (previously presented) The method of claim 21, wherein said anemia is caused by or associated with a disorder selected from the group consisting of chronic renal failure, aplastic anemia, hemolytic anemia, malignancy, an endocrine deficiency or is the result of chemotherapy.
- 31. (new) The method according to claim 21 wherein said glycosylation variant of erythropoeitin is epoetin or darbepoetin.
- 32. (new) The method according to claim 21, wherein said anemia is caused by chronic renal failure.